Abstract
Background The routine administration of supplemental oxygen to non-hypoxic patients with acute myocardial infarction has been abandoned for lack of mortality benefit. However, the benefits of continuous positive airway pressure (CPAP) use in patients hospitalized with acute cardiovascular disease and concomitant obstructive sleep apnea (OSA) remain to be elucidated.
Methods Using ICD-10-CM codes, we searched the 2016-2019 Nationwide Inpatient Sample for patients diagnosed with unstable angina, acute myocardial infarction (AMI), acute decompensated heart failure (ADHF), and atrial fibrillation with rapid ventricular response (AFRVR), who also carried a diagnosis of OSA. We identified in-hospital CPAP use with ICD-10-PCS codes. In-hospital death, length of stay (LOS) and hospital charges were compared between patients with and without OSA, and between OSA patients with and without CPAP use.
Results Our sample included 2,959,991 patients, of which 1.5% were diagnosed with UA, 30.3% with AMI, 37.5% with ADHF, and 45.8% with AF. OSA was present in 12.3%. Patients with OSA were more likely to be younger, male, smokers, obese, have chronic obstructive pulmonary disease, renal failure, and heart failure (p < 0.001 for all). Patients with OSA had significantly lower in-hospital mortality (aOR: 0.71, 95% CI [0.7-0.73]). Among patients with OSA, CPAP use significantly increased the odds of in-hospital death (aOR: 1.51, 95% CI [1.44-1.60]), LOS (adjusted mean difference of 1.49 days, 95% CI [1.43, 1.55]), and hospital charges (adjusted mean difference of $1168, 95% CI [273, 2062]).
Conclusion Our study showed that patients with recognized OSA and hospitalized for AMI, ADHF or AFRVR, who were not treated with CPAP, had significantly lower in-hospital mortality and resource utilization.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None of the authors in this manuscript received payment or services from a third party for any aspect of the submitted work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB required
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.
